Skip to main content
TipRanks
Go Ultimate75% OFF

Xbrane Biopharma AB (7XB0) Stock Price & Analysis

6 Followers

7XB0 Stock Chart & Stats

€0.95-€0.06(-5.54%)
At close: 5:30 PM GMT+1
€1€1.25€1.5Sep 28Oct 12Oct 28
Day’s Range
EUR 0.95 - EUR 0.98
52-Week Range
EUR 0.45 - EUR 1.55
Previous Close
EUR 1.01
Volume
N/A
Average Volume (3M)
64
Market Cap
EUR 21.25M
Enterprise Value
EUR 253.18M
Total Cash (Recent Filing)
EUR 37.41M
Total Debt (Recent Filing)
EUR 63.93M
Price to Earnings (P/E)
―
Beta
1.14
Next Earnings
Feb 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong TTM Revenue Growth

TTM revenue growth of 53.6% indicates meaningful commercial expansion and increasing demand for the company’s offerings. If growth can persist, it may improve operating leverage, support investment in the development pipeline, and strengthen the platform’s ability to reach sustainable scale.

Manageable Current Leverage

Low current debt relative to equity provides financial flexibility while the company funds development and commercialization activities. This comparatively manageable leverage profile can reduce near-term balance-sheet pressure and preserve capacity to respond to operating needs or pursue growth.

Focused Biosimilar Business Model

A focus on biosimilars targets lower-cost alternatives to established biologic medicines across immunology and oncology. The integrated model spans development, clinical work, and regulatory activities, creating a durable platform for building and commercializing follow-on biologic products.

Bears Say

Persistent Net Losses

The sizable TTM net loss and deeply negative operating margins show that revenue growth has not yet translated into sustainable profitability. Continued losses can constrain reinvestment, weaken financial resilience, and make future earnings dependent on successful commercialization and improved operating economics.

Significant Cash Burn

Materially negative operating and free cash flow indicates that the business is consuming cash rather than funding operations internally. Declining free cash flow increases reliance on external funding and can restrict the company’s ability to advance its pipeline without additional financing.

Volatile Capital Structure

Although leverage is currently low, the history of materially higher leverage shows that the capital structure has been volatile during periods of operating losses. This creates a longer-term financial risk because renewed cash needs could again pressure funding flexibility and shareholder returns.

Xbrane Biopharma AB News

7XB0 FAQ

What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was €0.45 and its highest was €1.55 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is €21.25M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Oct 30, 2026. The company reported -€0.052 earnings per share for the quarter.
Is Xbrane Biopharma AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -€0.052 in its last earnings report. Following the earnings report the stock price went down -13.83%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in DE:7XB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology